Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Sandro, Aquilanti"'
Autor:
Benjamin, Planquette, Laurent, Bertoletti, Anaïs, Charles-Nelson, Silvy, Laporte, Claire, Grange, Isabelle, Mahé, Gilles, Pernod, Antoine, Elias, Francis, Couturaud, Nicolas, Falvo, Marie Antoinette, Sevestre, Valérie, Ray, Alexis, Burnod, Nicolas, Brebion, Pierre-Marie, Roy, Miruna, Timar-David, Sandro, Aquilanti, Joel, Constans, Alessandra, Bura-Rivière, Dominique, Brisot, Gilles, Chatellier, Olivier, Sanchez, Guy, Meyer, Philippe, Girard, Patrick, Mismetti
Publikováno v:
Chest. 161(3)
Direct oral anticoagulants (DOACs) are an alternative to low-molecular-weight heparin for treating cancer-associated VTE.Is rivaroxaban as efficient and safe as dalteparin to treat patients with cancer-associated VTE?In a randomized open-label noninf
Autor:
Sandro Aquilanti, Ismail Elalamy, Meyer-Michel Samama, M.H. Horellou, J. Conard, Roberto A. Rached, Valérie G Mathieux, Geneviève Plu-Bureau
Publikováno v:
British Journal of Haematology. 123:327-334
The risk of venous thromboembolism (VTE) in the absence of prophylaxis was evaluated in a retrospective study of 47 women (84 pregnancies) with combined thrombophilia [heterozygous factor V Leiden (FVL) plus prothrombin (FII) 20210A mutation (group I
Autor:
Meyer-Michel, Samama, Roberto A, Rached, Marie-Hélène, Horellou, Sandro, Aquilanti, Valérie G, Mathieux, Geneviève, Plu-Bureau, Ismail, Elalamy, Jacqueline, Conard
Publikováno v:
British journal of haematology. 123(2)
The risk of venous thromboembolism (VTE) in the absence of prophylaxis was evaluated in a retrospective study of 47 women (84 pregnancies) with combined thrombophilia [heterozygous factor V Leiden (FVL) plus prothrombin (FII) 20210A mutation (group I